Journals / Acta Orthopaedica et Traumatologica Turcica / 2007 / Cilt: 41 - Sayı: 4

Evaluation of prognostic factors affecting recurrences and disease-free survival in extra-abdominal desmoid tumors

Ekstra-abdominal desmoid tümörlerde nüks ve hastalıksız sağkalımı etkileyen prognostik faktörlerin değerlendirilmesi

Pages
291–294
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In our series, no prognostic factor could be identified as having an association with the high recurrence rate.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: We investigated treatment results and the role of potential prognostic factors in patients treated by surgery with or without adjuvant radiotherapy for primary or recurrent extra-abdominal desmoid tumors.
📊
Key Findings & Data:Methods: The study included 38 patients (23 females, 15 males; mean age 24 years; range 5 to 61 years) who underwent surgical treatment for extra-abdominal desmoid tumors.
💡
Conclusion & Impact:Conclusion: In our series, no prognostic factor could be identified as having an association with the high recurrence rate.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hastalıksız sağkalım · Değerlendirme çalışmaları · Fibromatoz

Abstract

Objectives: We investigated treatment results and the role of potential prognostic factors in patients treated by surgery with or without adjuvant radiotherapy for primary or recurrent extra-abdominal desmoid tumors. Methods: The study included 38 patients (23 females, 15 males; mean age 24 years; range 5 to 61 years) who underwent surgical treatment for extra-abdominal desmoid tumors. Of these, eight patients (21.1%) already had recurrences before treatment. Involvement was in the upper extremity in 12 cases (31.6%), in the lower extremity in 22 cases (57.9%), and in the axial region in four cases (10.5%). Twenty-two patients received adjuvant radiotherapy following surgical resection. Survival was analyzed by the Kaplan-Meier method. The mean follow-up period was 7.3 years (2.5 to 228 months). Results: Twenty patients (52.6%) developed recurrences after treatment. Of these, recurrences were already present in six patients, and adjuvant radiotherapy was administered to 11 patients (55%). Recurrences developed at the irradiated site in eight patients, and in other regions in three patients. The mean disease-free survival was 38±8 months, and eightyear disease-free survival was 35.7±8.5%. Disease-free survival did not differ significantly between patients receiving adjuvant radiotherapy (47.9±7.9 months) and those treated with surgery alone (37.9±12.4 months), and between patients who developed a recurrence at the resection site (12.1±4.7 months) or at a different site (24.3±1.0 months) (p>0.05). None of the potential prognostic factors including gender, age, localization, surgical margin, or adjuvant irradiation were found to affect disease-free survival. Conclusion: In our series, no prognostic factor could be identified as having an association with the high recurrence rate.

Özet

Amaç: Tek başına cerrahi veya cerrahiyle beraber radyoterapi ile tedavi edilen primer ya da nüks ekstra-abdominal desmoid tümörlü hastalarda tedavi sonuçları ve prognostik faktörler araştırıldı. Çalışma planı: Çalışmaya, ekstra-abdominal desmoid tümör nedeniyle tedavi edilen 38 hasta (23 kadın, 15 erkek; ort. yaş 24; dağılım 5-61) alındı. Bu hastaların sekizi (%21.1) daha önceki cerrahi sonrasında nüks gelişen olgulardı. Tümörlerin 12’si (%31.6) üst ekstremitede, 22’si (%57.9) alt ekstremitede, dördü (%10.5) aksiyel bölgede görüldü. Primer cerrahi rezeksiyon sonrasında 22 hastaya radyoterapi uygulandı. Sağkalım analizi için Kaplan-Meier yöntemi kullanıldı. Hastalar ortalama 7.3 yıl (dağılım 2.5-228 ay) takip edildi. Sonuçlar: Tedaviden sonra 20 hastada (%52.6) nüks gelişti. Bu hastaların altısında tedavi başlangıcında da nüks vardı. Nüks gelişen 20 hastanın 11’i (%55) adjuvan radyoterapi görmüştü. Nüksler, üç hastada ilk radyoterapi bölgesinin dışında, sekiz hastada daha önce radyoterapi uygulanmış bölgede görüldü. Ortalama hastalıksız sağkalım 38±8 ay, sekiz yıllık hastalıksız sağkalım %35.7±8.5 bulundu. Ortalama hastalıksız sağkalım adjuvan radyoterapi gören (47.9±7.9 ay) ve görmeyen olgular (37.9±12.4 ay) arasında ve rezeksiyon bölgesinde nüks gelişen olgular (12.1±4.7 ay) ile farklı bölgede nüks gelişen olgular (24.3±1.0 ay) arasında anlamlı farklılık göstermedi (p>0.05). Cinsiyet, yaş, yerleşim, sınır durumu ya da radyoterapi gibi potansiyel prognostik faktörlerin hiçbiri hastalıksız sağkalım üzerinde etkili bulunmadı. Çıkarımlar: Çalışmamızda yüksek nüks oranı ile ilişkili olabilecek herhangi bir prognostik faktör tanımlanamadı.

🔖

Cite This Article

ÖZGER, H., ERALP, L., TOKER, B., AĞAOĞLU, F., DİZDAR, Y. (2007). Evaluation of prognostic factors affecting recurrences and disease-free survival in extra-abdominal desmoid tumors. Acta Orthopaedica et Traumatologica Turcica, Cilt: 41 - Sayı: 4, 291–294. https://ajindex.com/articles/354111

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Anthony T, Rodriguez-Bigas MA, Weber TK, Petrelli NJ. Desmoid tumors. J Am Coll Surg 1996;182:369-77
  2. Mendez-Fernandez MA, Gard DA. The desmoid tumor: “benign” neoplasm, not a benign disease. Plast Reconstr Surg 1991;87:956-60
  3. Posner MC, Shiu MH, Newsome JL, Hajdu SI, Gaynor JJ, Brennan MF. The desmoid tumor. Not a benign disease. Arch Surg 1989;124:191-6
  4. Lewis JJ, Boland PJ, Leung DH, Woodruff JM, Brennan MF. The enigma of desmoid tumors. Ann Surg 1999;229:866-72
  5. Pritchard DJ, Nascimento AG, Petersen IA. Local control of extra-abdominal desmoid tumors. J Bone Joint Surg [Am] 1996;78:848-54
  6. Karakousis CP, Mayordomo J, Zografos GC, Driscoll DL. Desmoid tumors of the trunk and extremity. Cancer 1993; 72:1637-41
  7. Merchant NB, Lewis JJ, Woodruff JM, Leung DH, Brennan MF. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer 1999;86:2045-52
  8. Rock MG, Pritchard DJ, Reiman HM, Soule EH, Brewster RC. Extra-abdominal desmoid tumors. J Bone Joint Surg [Am] 1984;66:1369-74
  9. Reitamo JJ, Scheinin TM, Hayry P. The desmoid syndrome. New aspects in the cause, pathogenesis and treatment of the desmoid tumor. Am J Surg 1986;151:230-7
  10. Spear MA, Jennings LC, Mankin HJ, Spiro IJ, Springfield DS, Gebhardt MC, et al. Individualizing management of aggressive fibromatosis. Int J Radiat Oncol Biol Phys 1998;40:637-45
  11. Sherman NE, Romsdahl M, Evans H, Zagars G, Oswald MJ. Desmoid tumors: a 20-year radiotherapy experience. Int J Radiat Oncol Biol Phys 1990;19:37-40
  12. Goy BW, Lee SP, Eilber F, Dorey F, Eckardt J, Fu YS, et al. The role of adjuvant radiotherapy in the treatment of resectable desmoid tumors. Int J Radiat Oncol Biol Phys 1997;39:659-65
  13. Kamath SS, Parsons JT, Marcus RB, Zlotecki RA, Scarborough MT. Radiotherapy for local control of aggressive fibromatosis. Int J Radiat Oncol Biol Phys 1996;36:325-8
  14. Nuyttens JJ, Rust PF, Thomas CR Jr, Turrisi AT 3rd. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors: A comparative review of 22 articles. Cancer 2000;88:1517-23
  15. Dalen BP, Bergh PM, Gunterberg BU. Desmoid tumors: a clinical review of 30 patients with more than 20 years’ follow- up. Acta Orthop Scand 2003;74:455-9
  16. Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 1999;17:158-67
  17. Gronchi A, Casali PG, Mar